A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.
Rosenthal A et al. Br J Haematol. 2015 Sep 25. doi: 10.1111/bjh.13765. [Epub ahead of print].

Carfilzomib, pomalidomide, and dexamethasone (CPD) in patients with relapsed and/or refractory multiple myeloma.
Shah JJ et al. Blood. 2015 Sep 17. pii: blood-2015-05-643320. [Epub ahead of print].

A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapsed or Refractory Multiple Myeloma: NCIC Clinical Trials Group IND.191.
Hay AE et al. Leuk Lymphoma. 2015 Sep 17:1-9. [Epub ahead of print].

Panobinostat for the Treatment of Multiple Myeloma.
Laubach JP et al. Clin Cancer Res. 2015 Sep 11. pii: clincanres.0530.2015. [Epub ahead of print].

Daratumumab Monotherapy Is Effective in Multiple Myeloma.
[No authors listed]. Cancer Discov. 2015 Sep 10. [Epub ahead of print].

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
Garfall AL et al. N Engl J Med. 2015 Sep 10;373(11):1040-7. doi: 10.1056/NEJMoa1504542.

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Gupta N et al. J Hematol Oncol. 2015 Sep 4;8:103. doi: 10.1186/s13045-015-0198-1.

‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma – analysis of cardiac toxicity and predisposing factors.
Danhof S et al. Eur J Haematol. 2015 Sep 2. doi: 10.1111/ejh.12677. [Epub ahead of print]